121 related articles for article (PubMed ID: 14555295)
1. Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites.
Sandmann G; Siess W; Essler M
Eur J Med Res; 2003 Sep; 8(9):397-404. PubMed ID: 14555295
[TBL] [Abstract][Full Text] [Related]
2. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activation of human platelets by lysophosphatidic acid and adrenaline.
Nilsson U; Svensson SP; Grenegård M
Haematologica; 2002 Jul; 87(7):730-9; discussion 739. PubMed ID: 12091124
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid stimulation of platelets rapidly induces Ca2+-dependent dephosphorylation of cofilin that is independent of dense granule secretion and aggregation.
Pandey D; Goyal P; Siess W
Blood Cells Mol Dis; 2007; 38(3):269-79. PubMed ID: 17321765
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation.
Gueguen G; Gaigé B; Grévy JM; Rogalle P; Bellan J; Wilson M; Klaébé A; Pont F; Simon MF; Chap H
Biochemistry; 1999 Jun; 38(26):8440-50. PubMed ID: 10387090
[TBL] [Abstract][Full Text] [Related]
6. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K
Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483
[TBL] [Abstract][Full Text] [Related]
7. Effect of lysophospholipids on signaling in the human Jurkat T cell line.
Xu Y; Casey G; Mills GB
J Cell Physiol; 1995 Jun; 163(3):441-50. PubMed ID: 7775587
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Xu Y; Gaudette DC; Boynton JD; Frankel A; Fang XJ; Sharma A; Hurteau J; Casey G; Goodbody A; Mellors A
Clin Cancer Res; 1995 Oct; 1(10):1223-32. PubMed ID: 9815916
[TBL] [Abstract][Full Text] [Related]
9. Propofol inhibits human platelet aggregation induced by proinflammatory lipid mediators.
Fourcade O; Simon MF; Litt L; Samii K; Chap H
Anesth Analg; 2004 Aug; 99(2):393-8, table of contents. PubMed ID: 15271713
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.
Khandoga AL; Fujiwara Y; Goyal P; Pandey D; Tsukahara R; Bolen A; Guo H; Wilke N; Liu J; Valentine WJ; Durgam GG; Miller DD; Jiang G; Prestwich GD; Tigyi G; Siess W
Platelets; 2008 Sep; 19(6):415-27. PubMed ID: 18925509
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of migration-resistant hydroxyethoxy analogues of lysophosphatidic acid.
Qian L; Xu Y; Arai H; Aoki J; McIntyre TM; Prestwich GD
Org Lett; 2003 Nov; 5(24):4685-8. PubMed ID: 14627415
[TBL] [Abstract][Full Text] [Related]
12. Neurotransmitter release from lysophosphatidic acid stimulated PC12 cells: involvement of lysophosphatidic acid receptors.
Shiono S; Kawamoto K; Yoshida N; Kondo T; Inagami T
Biochem Biophys Res Commun; 1993 Jun; 193(2):667-73. PubMed ID: 8390248
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid activates phosphoinositide 3-kinase and phospholipase C in human platelets: inhibitory effects of Wortmannin on phosphoinositide 3-kinase and aggregation.
Zhang J; Rittenhouse SE
Biochem Biophys Res Commun; 1995 Jun; 211(2):484-90. PubMed ID: 7794259
[TBL] [Abstract][Full Text] [Related]
14. Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate.
Motohashi K; Shibata S; Ozaki Y; Yatomi Y; Igarashi Y
FEBS Lett; 2000 Feb; 468(2-3):189-93. PubMed ID: 10692584
[TBL] [Abstract][Full Text] [Related]
15. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.
Haserück N; Erl W; Pandey D; Tigyi G; Ohlmann P; Ravanat C; Gachet C; Siess W
Blood; 2004 Apr; 103(7):2585-92. PubMed ID: 14645014
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.
Jin Y; Knudsen E; Wang L; Maghazachi AA
Eur J Immunol; 2003 Aug; 33(8):2083-9. PubMed ID: 12884281
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid triggers calcium entry through a non-store-operated pathway in human neutrophils.
Itagaki K; Kannan KB; Hauser CJ
J Leukoc Biol; 2005 Feb; 77(2):181-9. PubMed ID: 15522918
[TBL] [Abstract][Full Text] [Related]
18. Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
Park KS; Kim MK; Im DS; Bae YS
Biochem Pharmacol; 2007 Mar; 73(5):675-81. PubMed ID: 17161826
[TBL] [Abstract][Full Text] [Related]
19. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway.
Pamuklar Z; Lee JS; Cheng HY; Panchatcharam M; Steinhubl S; Morris AJ; Charnigo R; Smyth SS
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):555-61. PubMed ID: 18202325
[TBL] [Abstract][Full Text] [Related]
20. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
